|
1
|
Liotta LA, Kleinerman J and Saidel GM:
Quantitative relationships of intravascular tumor cells, tumor
vessels, and pulmonary metastases following tumor implantation.
Cancer Res. 34:997–1004. 1974.PubMed/NCBI
|
|
2
|
Camara O, Rengsberger M, Egbe A, Koch A,
Gajda M, Hammer U, Jörke C, Rabenstein C, Untch M and Pachmann K:
The relevance of circulating epithelial tumor cells (CETC) for
therapy monitoring during neoadjuvant (primary systemic)
chemotherapy in breast cancer. Ann Oncol. 18:1484–1492. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Scher HI, Jia X, de Bono JS, Fleisher M,
Pienta KJ, Raghavan D and Heller G: Circulating tumour cells as
prognostic markers in progressive, castration-resistant prostate
cancer: A reanalysis of IMMC38 trial data. Lancet Oncol.
10:233–239. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
A L Reid, Millward M, Pearce R, Lee M,
Frank MH, Ireland A, Monshizadeh L, Rai T, Heenan P, Medic S, et
al: Markers of circulating tumour cells in the peripheral blood of
patients with melanoma correlate with disease recurrence and
progression. Br J Dermatol. 168:85–92. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lu CY, Tsai HL, Uen YH, Hu HM, Chen CW,
Cheng TL, Lin SR and Wang JY: Circulating tumor cells as a
surrogate marker for determining clinical outcome to mFOLFOX
chemotherapy in patients with stage III colon cancer. Br J Cancer.
108:791–797. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Arai Y, Kanamaru H, Yoshimura K, Okubo K,
Kamoto T and Yoshida O: Incidence of lymph node metastasis and its
impact on long-term prognosis in clinically localized prostate
cancer. Int J Urol. 5:459–465. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Vona G, Sabile A, Louha M, Sitruk V,
Romana S, Schütze K, Capron F, Franco D, Pazzagli M, Vekemans M, et
al: Isolation by size of epithelial tumor cells: A new method for
the immunomorphological and molecular characterization of
circulating tumor cells. Am J Pathol. 156:57–63. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Talasaz AH, Powell AA, Huber DE, Berbee
JG, Roh KH, Yu W, Xiao W, Davis MM, Pease RF, Mindrinos MN, et al:
Isolating highly enriched populations of circulating epithelial
cells and other rare cells from blood using a magnetic sweeper
device. Proc Natl Acad Sci USA. 106:3970–3975. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
He W, Wang H, Hartmann LC, Cheng JX and
Low PS: In vivo quantitation of rare circulating tumor cells by
multiphoton intravital flow cytometry. Proc Natl Acad Sci USA.
104:11760–11765. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ito H, Kanda T, Nishimaki T, Sato H,
Nakagawa S and Hatakeyama K: Detection and quantification of
circulating tumor cells in patients with esophageal cancer by
real-time polymerase chain reaction. J Exp Clin Cancer Res.
23:455–464. 2004.PubMed/NCBI
|
|
12
|
Honma H, Kanda T, Ito H, Wakai T, Nakagawa
S, Ohashi M, Koyama Y, Valera VA, Akazawa K and Hatakeyama K:
Squamous cell carcinoma-antigen messenger RNA level in peripheral
blood predicts recurrence after resection in patients with
esophageal squamous cell carcinoma. Surgery. 139:678–685. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nagrath S, Sequist LV, Maheswaran S, Bell
DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky
A, et al: Isolation of rare circulating tumour cells in cancer
patients by microchip technology. Nature. 450:1235–1239. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cohen SJ, Punt CJ, Iannotti N, Saidman BH,
Sabbath KD, Gabrail NY, Picus J, Morse M, Mitchell E, Miller MC, et
al: Relationship of circulating tumor cells to tumor response,
progression-free survival, and overall survival in patients with
metastatic colorectal cancer. J Clin Oncol. 26:3213–3221. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Riethdorf S, Fritsche H, Müller V, Rau T,
Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Jänicke F, et al:
Detection of circulating tumor cells in peripheral blood of
patients with metastatic breast cancer: A validation study of the
cell search system. Clin Cancer Res. 13:920–928. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Davis JW, Nakanishi H, Kumar VS,
Bhadkamkar VA, McCormack R, Fritsche HA, Handy B, Gornet T and
Babaian RJ: Circulating tumor cells in peripheral blood samples
from patients with increased serum prostate specific antigen:
Initial results in early prostate cancer. J Urol. 179:2187–2191;
discussion 2191. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hou JM, Greystoke A, Lancashire L,
Cummings J, Ward T, Board R, Amir E, Hughes S, Krebs M, Hughes A,
et al: Evaluation of circulating tumor cells and serological cell
death biomarkers in small cell lung cancer patients undergoing
chemotherapy. Am J Pathol. 175:808–816. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Książkiewicz M, Markiewicz A and Zaczek
AJ: Epithelial-mesenchymal transition: A hallmark in metastasis
formation linking circulating tumor cells and cancer stem cells.
Pathobiology. 79:195–208. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Gorges TM, Tinhofer I, Drosch M, Röse L,
Zollner TM, Krahn T and von Ahsen O: Circulating tumour cells
escape from EpCAM-based detection due to epithelial-to-mesenchymal
transition. BMC Cancer. 12:1782012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kim NW, Piatyszek MA, Prowse KR, Harley
CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay
JW: Specific association of human telomerase activity with immortal
cells and cancer. Science. 266:2011–2015. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Blackburn EH: Telomere states and cell
fates. Nature. 408:53–56. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
22
|
Fujiwara T, Kagawa S, Kishimoto H, Endo Y,
Hioki M, Ikeda Y, Sakai R, Urata Y, Tanaka N and Fujiwara T:
Enhanced antitumor efficacy of telomerase-selective oncolytic
adenoviral agent OBP-401 with docetaxel: Preclinical evaluation of
chemovirotherapy. Int J Cancer. 119:432–440. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ito H, Inoue H, Sando N, Kimura S, Gohda
K, Sato J, Murakami K, Ito S, Odaka N, Satodate H and Kudo SE:
Prognostic impact of detecting viable circulating tumour cells in
gastric cancer patients using a telomerase-specific viral agent: A
prospective study. BMC Cancer. 12:3462012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
World Health Organization, . International
Agency for Research on Cancer. GLOBOCAN 2012. Estimated Cancer
Incidence, Mortality and Prevalence World Wide in 2012. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspxAccessed
June 9, 2014.
|
|
25
|
Lin HK, Zheng S, Williams AJ, Balic M,
Groshen S, Scher HI, Fleisher M, Stadler W, Datar RH, Tai YC and
Cote RJ: Portable filter-based microdevice for detection and
characterization of circulating tumor cells. Clin Cancer Res.
16:5011–5018. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zheng S, Lin HK, Lu B, Williams A, Datar
R, Cote RJ and Tai YC: 3D microfilter device for viable circulating
tumor cell (CTC) enrichment from blood. Biomed Microdevices.
13:203–213. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ito H, Inoue H, Kimura S, Ohmori T,
Ishikawa F, Gohda K and Sato J: Prognostic impact of the number of
viable circulating cells with high telomerase activity in gastric
cancer patients: A prospective study. Int J Oncol. 45:227–234.
2014.PubMed/NCBI
|
|
28
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern Cooperative Oncology Group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sobin LH, Gospodarowicz MK and Wittekind
C: TNM Classification of Malignant Tumours. 7th. Blackwell
Publishing Ltd.; Oxford: 2010
|
|
30
|
Kim SJ, Masago A, Tamaki Y, Akazawa K,
Tsukamoto F, Sato J, Ozawa T, Tsujino Y and Noguchi S: A novel
approach using telomerase-specific replication-selective adenovirus
for detection of circulating tumor cells in breast cancer patients.
Breast Cancer Res Treat. 128:765–773. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Cristofanilli M, Budd GT, Ellis MJ,
Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ,
Terstappen LW and Hayes DF: Circulating tumor cells, disease
progression, and survival in metastatic breast cancer. N Engl J
Med. 351:781–791. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Moreno JG, Miller MC, Gross S, Allard WJ,
Gomella LG and Terstappen LW: Circulating tumor cells predict
survival in patients with metastatic prostate cancer. Urology.
65:713–718. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Krebs MG, Sloane R, Priest L, Lancashire
L, Hou JM, Greystoke A, Ward TH, Ferraldeschi R, Hughes A, Clack G,
et al: Evaluation and prognostic significance of circulating tumor
cells in patients with non-small-cell lung cancer. J Clin Oncol.
29:1556–1563. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Katsumata K, Sumi T, Mori Y, Hisada M,
Tsuchida A and Aoki T: Detection and evaluation of epithelial cells
in the blood of colon cancer patients using RT-PCR. Int J Clin
Oncol. 11:385–389. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Bonsing BA, Beerman H, Kuipers-Dijkshoorn
N, Fleuren GJ and Cornelisse CJ: High levels of DNA index
heterogeneity in advanced breast carcinomas. Evidence for DNA
ploidy differences between lymphatic and hematogenous metastases.
Cancer. 71:382–391. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Klijanienko J, el-Naggar AK, de Braud F,
Rodriguez-Peralto JL, Rodriguez R, Itzhaki M, Russo A, Janot F,
Luboinski B and Cvitkovic E: Tumor vascularization, mitotic index,
histopathologic grade, and DNA ploidy in the assessment of 114 head
and neck squamous cell carcinomas. Cancer. 75:1649–1656. 1995.
View Article : Google Scholar : PubMed/NCBI
|
